Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases

Yaron Meirow, Michal Baniyash*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Chronic inflammation arising in a diverse range of non-cancerous and cancerous diseases, dysregulates immunity and exposes patients to a variety of complications. These include immunosuppression, tissue damage, cardiovascular diseases and more. In cancer, chronic inflammation and related immunosuppression can directly support tumor growth and dramatically reduce the efficacies of traditional treatments, as well as novel immune-based therapies, which require a functional immune system. Nowadays, none of the immune biomarkers, regularly used by clinicians can sense a developing chronic inflammation, thus complications can only be detected upon their appearance. This review focuses on the necessity for such immune status biomarkers, which could predict complications prior to their appearance. Herein we bring examples for the use of cellular and molecular biomarkers in diagnosis, prognosis and follow-up of patients suffering from various cancers, for prediction of response to immune-based anti-cancer therapy and for prediction of cardiovascular disease in type 2 diabetes patients. Monitoring such biomarkers is expected to have a major clinical impact in addition to unraveling of the entangled complexity underlying dysregulated immunity in chronic inflammation. Thus, newly discovered biomarkers and those that are under investigation are projected to open a new era towards combating the silent damage induced by chronic inflammation.

Original languageAmerican English
Pages (from-to)1089-1101
Number of pages13
JournalCancer Immunology, Immunotherapy
Issue number8
StatePublished - 1 Aug 2017

Bibliographical note

Funding Information:
The authors acknowledge Kerem Ben-Meir, Leonor Daniel and Ivan Mikula, who helped in the production of this review. The authors gratefully acknowledge the support of the Society of Research Associates of the Lautenberg Center and the Harold B. Abramson Chair in Immunology. They also thank the Grant support by the Israel Science Foundation (ISF), Joint Program between the Israel Science Foundation (ISF) and the National Natural Science Foundation of China (NSFC) the Israeli Ministry of Health, the Joint German-Israeli Research Program (DKFZ), the Israel Cancer Research Fund (ICRF), Israeli Ministry of Economy Chief Scientist’s program for Industrial Application of Academic Research (NOFAR), and the Joseph and Matilda Melnick Funds.

Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany.


  • Cancer
  • Chronic inflammation
  • Immune biomarkers
  • Immunosuppression
  • MDSC
  • Type 2 diabetes


Dive into the research topics of 'Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases'. Together they form a unique fingerprint.

Cite this